375 related articles for article (PubMed ID: 17400844)
21. Effect of parity on bone mineral density among postmenopausal Saudi Arabian women.
Sadat-Ali M; Al-Habdan I; Al-Mulhim AA; El-Hassan AY
Saudi Med J; 2005 Oct; 26(10):1588-90. PubMed ID: 16228061
[TBL] [Abstract][Full Text] [Related]
22. Association of grip strength change with menopausal bone loss and related fractures: a population-based follow-up study.
Sirola J; Rikkonen T; Tuppurainen M; Jurvelin JS; Kröger H
Calcif Tissue Int; 2006 Apr; 78(4):218-26. PubMed ID: 16604281
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
[TBL] [Abstract][Full Text] [Related]
24. Absolute fracture risk assessment using lumbar spine and femoral neck bone density measurements: derivation and validation of a hybrid system.
Leslie WD; Lix LM;
J Bone Miner Res; 2011 Mar; 26(3):460-7. PubMed ID: 20839285
[TBL] [Abstract][Full Text] [Related]
25. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
[TBL] [Abstract][Full Text] [Related]
26. Risk factors related to the presence and severity of hot flushes in mid-aged Ecuadorian women.
Chedraui P; Aguirre W; Calle A; Hidalgo L; León-León P; Miranda O; Martínez N; Mendoza M; Narváez J; Sánchez H; Schwager G; Quintero JC; Zambrano B; Aguilar A; Martínez MA; Rivera R; Ruilova I
Maturitas; 2010 Apr; 65(4):378-82. PubMed ID: 20031350
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for clinical fractures among postmenopausal women: a 10-year prospective study.
van Geel TA; Geusens PP; Nagtzaam IF; van der Voort DJ; Schreurs CM; Rinkens PE; Dinant GJ
Menopause Int; 2007 Sep; 13(3):110-5. PubMed ID: 17785036
[TBL] [Abstract][Full Text] [Related]
28. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study.
Bagger YZ; Tankó LB; Alexandersen P; Hansen HB; Møllgaard A; Ravn P; Qvist P; Kanis JA; Christiansen C
Bone; 2004 Apr; 34(4):728-35. PubMed ID: 15050905
[TBL] [Abstract][Full Text] [Related]
29. Osteoarthritis, bone density, postural stability, and osteoporotic fractures: a population based study.
Jones G; Nguyen T; Sambrook PN; Lord SR; Kelly PJ; Eisman JA
J Rheumatol; 1995 May; 22(5):921-5. PubMed ID: 8587083
[TBL] [Abstract][Full Text] [Related]
30. Cytochrome gene polymorphisms, serum estrogens, and hot flushes in midlife women.
Visvanathan K; Gallicchio L; Schilling C; Babus JK; Lewis LM; Miller SR; Zacur H; Flaws JA
Obstet Gynecol; 2005 Dec; 106(6):1372-81. PubMed ID: 16319265
[TBL] [Abstract][Full Text] [Related]
31. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
Gallagher JC; Shi H; Mirkin S; Chines AA
Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
[TBL] [Abstract][Full Text] [Related]
32. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.
Barrett-Connor E; Wehren LE; Siris ES; Miller P; Chen YT; Abbott TA; Berger ML; Santora AC; Sherwood LM
Menopause; 2003; 10(5):412-9. PubMed ID: 14501602
[TBL] [Abstract][Full Text] [Related]
33. Bisphosphonate dose and incidence of fractures in postmenopausal osteoporosis.
Makras P; Hamdy NA; Zwinderman AH; Ballieux BE; Papapoulos SE
Bone; 2009 May; 44(5):766-71. PubMed ID: 19442613
[TBL] [Abstract][Full Text] [Related]
34. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
[TBL] [Abstract][Full Text] [Related]
35. Pattern of bone loss in surgical menopause: a preliminary report.
Chittacharoen A; Theppisai U; Sirisriro R; Thanantaseth C
J Med Assoc Thai; 1997 Nov; 80(11):731-7. PubMed ID: 9385771
[TBL] [Abstract][Full Text] [Related]
36. Effect of microdose transdermal 17beta-estradiol compared with raloxifene in the prevention of bone loss in healthy postmenopausal women: a 2-year, randomized, double-blind trial.
Schaefers M; Muysers C; Alexandersen P; Christiansen C
Menopause; 2009; 16(3):559-65. PubMed ID: 19423999
[TBL] [Abstract][Full Text] [Related]
37. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study.
Salaffi F; Cimmino MA; Malavolta N; Carotti M; Di Matteo L; Scendoni P; Grassi W;
J Rheumatol; 2007 Jul; 34(7):1551-60. PubMed ID: 17516618
[TBL] [Abstract][Full Text] [Related]
38. The relationship between serum adiponectin level and anthropometry, bone mass, osteoporotic fracture risk in postmenopausal women.
Ozkurt B; Ozkurt ZN; Altay M; Aktekin CN; Cağlayan O; Tabak Y
Eklem Hastalik Cerrahisi; 2009; 20(2):78-84. PubMed ID: 19619110
[TBL] [Abstract][Full Text] [Related]
39. Relation of alleles of the collagen type Ialpha1 gene to bone density and the risk of osteoporotic fractures in postmenopausal women.
Uitterlinden AG; Burger H; Huang Q; Yue F; McGuigan FE; Grant SF; Hofman A; van Leeuwen JP; Pols HA; Ralston SH
N Engl J Med; 1998 Apr; 338(15):1016-21. PubMed ID: 9535665
[TBL] [Abstract][Full Text] [Related]
40. Effects of bazedoxifene in nonflushing postmenopausal women: a randomized phase 2 trial.
Bachmann G; Crosby U; Feldman RA; Ronkin S; Constantine GD
Menopause; 2011 May; 18(5):508-14. PubMed ID: 21289525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
